Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06237712
Other study ID # NL84462.078.23
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date January 26, 2024
Est. completion date July 2026

Study information

Verified date February 2024
Source Erasmus Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

With this research the investigators want to study how patients with chronic kidney disease respond to different sodium- and potassium salts. Potassium salts can prevent kidney damage and cardiovascular disease, however patients with chronic kidney disease can responds differently. Extra potassium can increase the amount of potassium in the blood and extra chloride can cause acidosis. With this study the investigators will gain more insight in how patients with chronic kidney disease respond to sodium and potassium salts and which one is more favorable.This information can then be used to guide the application of salt substitutes and dietary adjustments in patients with chronic kidney disease.


Description:

Rationale: Patients with chronic kidney disease (CKD) consume a low potassium diet which is associated with progressive CKD and cardiovascular disease. Increasing dietary potassium intake to recommended levels may therefore improve cardiorenal outcomes, but the response to increased potassium intake in patients with CKD is unclear. Therefore, the investigators recently tested the response to 40 mmol potassium chloride in patients with CKD and showed that this is generally well-tolerated. However, patients did develop mild hyperchloremic metabolic acidosis, which may offset the beneficial effects of potassium. The investigators hypothesize that this is a form of chloride-induced acidosis that may be prevented by giving potassium with a different anion than chloride. To further investigate this, the investigators propose to test the response to five different sodium and potassium salts in patients with CKD. These results should inform us on how to best correct a potassium-deficient diet in patients with CKD. Objective: To test the effects of five different sodium and potassium salts in patients with CKD. Study design: Investigator-initiated, single-center, placebo-controlled double-blind randomized crossover study. Study population: Adult outpatients (age ≥ 18 years) with CKD stage G3b or G4 using renin-angiotensin-aldosterone system inhibitors (RAAS-I). Intervention: Capsules with 40 mmol potassium chloride, potassium bicarbonate, potassium gluconate, sodium bicarbonate, sodium chloride or placebo (3 x 3 capsules per day). Main study parameters/endpoints: Difference in plasma bicarbonate after treatment. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The study lasts 6 weeks and consists of 7 visits that will consist of blood sampling, 24-hour urine collection and spot urine collection. We will also provide an automated blood pressure measuring device for at home blood pressure measurements. Although these procedures are time-consuming and may be experienced as burdensome, they are all routine clinical measurements and safe. Patients may experience a pill-burden. The two risks of the salt supplements are hyperkalemia (with potassium salts) and hypertension (with sodium salts). Based on our previous studies a minority of patients is expected to develop these side-effects (< 12%). Safety measures to prevent, monitor and treat these side-effects are included in the study protocol. There are no direct benefits for patients participating in this trial, but the results will contribute to a better understanding on the feasibility of dietary modifications and salt substitution in patients with CKD to improve health. Patients will be reimbursed for their participation.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 31
Est. completion date July 2026
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (= 18 years) - CKD G3b or G4 (44 - 15 ml/min/1.73 m2) - Use of RAAS-I (ACE-inhibitor or angiotensin receptor blocker, ARB) Exclusion Criteria: - Use of any of the following drugs or supplements: mineralocorticoid receptor antagonists, potassium-sparing diuretics, oral potassium binders, immunosuppressive medication, tolvaptan, acetazolamide, topiramate, sodium bicarbonate. - Patients using double RAAS blockade (i.e., ACE-inhibitor + ARB). - Metabolic alkalosis (plasma bicarbonate >27 mmol/L) at last outpatient visit - Kidney transplant recipients - Patients with an active gastro-intestinal ulcer - Patients with previous history of ventricular cardiac arrhythmia - Patients with a life expectancy < 6 months - Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the research team - Women who are pregnant, breastfeeding or consider pregnancy in the coming 7 weeks - Patients with chronic respiratory acidosis in previous medical history - Hyperkalemia (plasma potassium >5.5 mmol/L) at V0

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Dietary supplement consisting of 40 mmol/daily of potassium chloride
The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
Dietary supplement consisting of 40 mmol/daily of potassium gluconate
The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
Dietary supplement consisting of 40 mmol/daily of potassium bicarbonate
The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
Dietary supplement consisting of 40 mmol/daily of sodium chloride
The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
Dietary supplement consisting of 40 mmol/daily of sodium bicarbonate
The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
Placebo caps
The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.

Locations

Country Name City State
Netherlands ErasmusMC Rotterdam Zuid-Holland

Sponsors (1)

Lead Sponsor Collaborator
Erasmus Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma bicarbonate by blood draw The absolute difference per treatment group in measured plasma bicarbonate after treatment.
After each treatment of 5 days, plasma bicarbonate will be measured by blood sampling.
The difference between the groups (treatments) will be the main outcome and comparator.
After 5 days of intervention
Secondary Plasma electrolyte levels Na, Cl, K, Mg, Ca, Phosphate (all in mmol/L) After 5 days of intervention
Secondary Urinary citrate Urinary citrate in mmol/24h After 5 days of intervention
Secondary Urinary ammonia urinary ammonia in mmol/24, calculated using the Berthelot method After 5 days of intervention
Secondary Titratable acid Titratable acid = (0.067) × (mLs NaOH (sample titration) - mLs NaOH (blank titration)) × 75/ mLs of sample After 5 days of intervention
Secondary Net acid excretion Net acid excretion unit/24h, formula = sum of the titratable acid and concentration of ammonia minus the concentration of bicarbonate. After 5 days of intervention
Secondary Potential renal acid load PRAL (mEq/d) = 0.49 × protein (g/d) + 0.037 × phosphate (mg/d) - 0.021 × potassium (mg/d) - 0.026 × magnesium (mg/d) - 0.013 × calcium (mg/d). After 5 days of intervention
Secondary Body weight Weight measured by a scale in kilograms After 5 days of intervention
Secondary Blood pressure Systolic and diastolic blood pressure measured 2 times daily during the study, so 20 times during the 5 days of supplement usage. Measurements will be done in the morning and evening measured twice in seated position with an automatic blood pressure monitor. 2 measurements in the morning and evening for 5 days per treatment repeated for 6 treatments in total
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03277911 - Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases N/A
Active, not recruiting NCT04008810 - Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
Completed NCT05144971 - StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
Active, not recruiting NCT05356325 - FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.
Not yet recruiting NCT04491669 - Screening of Gastrointestinal Tract Bleeding Causes Among Chronic Renal Failure Patients
Completed NCT04709120 - Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection
Terminated NCT03277183 - Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Phase 4
Enrolling by invitation NCT04491227 - Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
Recruiting NCT06279429 - Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia N/A
Recruiting NCT03501745 - Smart-CKD/BP Study N/A
Recruiting NCT04708743 - The Tongue Features Associated With Chronic Kidney Disease
Recruiting NCT06416761 - Genetics in the Progression of Nephropathies
Completed NCT04119570 - CKD Report Card Pilot Trial N/A
Completed NCT06374043 - Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. Phase 4
Not yet recruiting NCT06094920 - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Phase 4
Recruiting NCT04819217 - Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease N/A
Completed NCT05970094 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Withdrawn NCT04782297 - Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)
Recruiting NCT05784389 - Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5 N/A
Recruiting NCT04630132 - Renal Ageing-sarcopenia Network